Short Interest in CEL-SCI Co. (NYSEAMERICAN:CVM) Expands By 56.3%

CEL-SCI Co. (NYSEAMERICAN:CVM) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,006,033 shares, a growth of 56.3% from the January 31st total of 643,794 shares. Approximately 7.7% of the shares of the stock are short sold. Based on an average trading volume of 172,727 shares, the days-to-cover ratio is currently 5.8 days.

CEL-SCI (CVM) traded up $0.06 during trading on Wednesday, reaching $1.85. 29,337 shares of the company’s stock traded hands, compared to its average volume of 194,431. The firm has a market capitalization of $25.49, a price-to-earnings ratio of -0.66 and a beta of -1.29. CEL-SCI has a 12-month low of $1.46 and a 12-month high of $4.00.

CEL-SCI (NYSEAMERICAN:CVM) last posted its quarterly earnings data on Monday, February 12th. The company reported ($0.53) EPS for the quarter. The company had revenue of $0.11 million for the quarter.

A hedge fund recently bought a new stake in CEL-SCI stock. Anson Funds Management LP acquired a new stake in CEL-SCI Co. (NYSEAMERICAN:CVM) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 263,158 shares of the company’s stock, valued at approximately $423,000. CEL-SCI comprises 0.3% of Anson Funds Management LP’s investment portfolio, making the stock its 27th largest holding. Anson Funds Management LP owned 1.88% of CEL-SCI at the end of the most recent reporting period.

COPYRIGHT VIOLATION WARNING: “Short Interest in CEL-SCI Co. (NYSEAMERICAN:CVM) Expands By 56.3%” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at


CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with's FREE daily email newsletter.

Leave a Reply